Tocilizumab for the Treatment of COVID-19 Among Hospitalized Patients: A Matched Retrospective Cohort Analysis

BACKGROUND: There is currently no single treatment that mitigates all harms caused by severe acute respiratory syndrome coronavirus 2 infection. Tocilizumab, an interleukin-6 antagonist, may have a role as an adjunctive immune-modulating therapy. METHODS: This was an observational retrospective stud...

Descripción completa

Detalles Bibliográficos
Autores principales: Ignatius, Elisa H, Wang, Kunbo, Karaba, Andrew, Robinson, Matthew, Avery, Robin K, Blair, Paul, Chida, Natasha, Jain, Tania, Petty, Brent G, Siddiqui, Zishan, Melia, Michael T, Auwaerter, Paul G, Xu, Yanxun, Garibaldi, Brian T
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Oxford University Press 2020
Materias:
Major Articles
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7798657/
https://www.ncbi.nlm.nih.gov/pubmed/33537364
http://dx.doi.org/10.1093/ofid/ofaa598

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7798657/
https://www.ncbi.nlm.nih.gov/pubmed/33537364
http://dx.doi.org/10.1093/ofid/ofaa598

Ejemplares similares